On Friday, pharmaceutical giant Sun Pharma said that its subsidiary had acquired the Uractiv portfolio from Romania’s Fiterman Pharma.

The company’s subsidiary – SC Terapia SA in Romania, acquired the Uractiv product portfolio, which includes food supplements, minerals, vitamins and adjuvants, cosmetics and medical devices to maintain urinary tract health.
However, the Mumbai-based drugmaker did not disclose the deal’s financial details.

In a statement, Sun Pharma said that Uractiv is the leading brand of its kind in Romania, trusted by consumers for more than ten years. The product portfolio consists of 12 SKUs (stock-keeping units) and generates approximately $8.7 million in annual revenue. These products are suitable for adults and children.

• Vedanta Outlook for the Week (April 29, 2024 – May 03, 2024)
• Tata Steel Outlook for the Week (April 29, 2024 – May 03, 2024)
• PFC Outlook for the Week (April 29, 2024 – May 03, 2024)
• Piramal Enterprises Outlook for the Week (April 29, 2024 – May 03, 2024)
• MANAPPURAM Outlook for the Week (April 29, 2024 – May 03, 2024)

He added that the drugmaker has a strong presence in Romania, and Trapia is the Number one player in the generic and over-the-counter market. “We will use our strong marketing and distribution strengths to develop these brands further,” said Jean-Ville. Shares in the company were trading 0.35% lower at Rs 900.20 apiece on the BSE.